RT Journal Article SR Electronic T1 Epidemic preparedness - Leishmania tarentolae as an easy-to-handle tool to produce antigens for viral diagnosis: application to COVID-19 JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.07.05.21260035 DO 10.1101/2021.07.05.21260035 A1 Ilaria Varotto-Boccazzi A1 Alessandro Manenti A1 Francesca Dapporto A1 Louise J. Gourlay A1 Beatrice Bisaglia A1 Paolo Gabrieli A1 Federico Forneris A1 Silvia Faravelli A1 Valentina Bollati A1 Gian Vincenzo Zuccotti A1 Emanuele Montomoli A1 Sara Epis A1 Claudio Bandi YR 2021 UL http://medrxiv.org/content/early/2021/07/07/2021.07.05.21260035.abstract AB To control future epidemics, discovery platforms are urgently needed, for the rapid development of diagnostic assays. Molecular diagnostic tests for COVID-19 emerged shortly after the isolation of SARS-CoV-2, however, serological tests based on antiviral antibody detection, revealing previous exposure to the virus, required longer developmental phases, due to the need for correctly folded and glycosylated antigens. The delay between the identification of a new virus and the development of reliable serodiagnostic tools limits our readiness for the control of a future epidemic. In this context, we propose the protozoan Leishmania tarentolae as an easy-to-handle micro-factory for the rapid production of viral antigens, to be used at the forefront of emerging epidemics. As a study model, we engineered L. tarentolae to express the SARS-CoV-2 Receptor Binding Domain (RBD) and report the ability of the purified RBD antigen to detect SARS-CoV-2 infection, with a sensitivity and reproducibility comparable to that of a reference antigen produced in human cells. This is the first application of an antigen produced in L. tarentolae for the serodiagnosis of a Coronaviridae infection. Based on our results, we propose L. tarentolae as an effective system for viral antigen production, even in countries that lack high-tech cell factories.Competing Interest StatementThe organism Lt-RBD and its potential application has been described in the patent application No. 02021000004160; Publication Date 23.02.2021.Funding StatementSara Epis received funding from Erogazione liberale per le attivita' di ricerca sul Coronavirus (grant agreement No. LIB_VT20_COVID_19_SEPIS). Claudio Bandi and Gian Vincenzo Zuccotti have received funding from Erogazione liberale per le attivita' di ricerca sul Coronavirus (grant agreement No. LIB_VT20_COVID_19_GZUCCOTTI). VisMederi Research provided funding support for reagents and serological assay. Research of Federico Forneris was supported by the Italian Association for Cancer Research (AIRC, My First AIRC Grant id. 20075) and by the NATO Science for Peace and Security Program (grant id. SPS G5701). UNICORN was supported by the Funding Action Ricerche Emergenza coronavirus, University of Milan, 2020.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of the University of Milan, approval number 17/20, approval date March 6, 2020All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSupplementary material is available in this Medrxiv